Strong collaboration has always been at the heart of SPIOMET4HEALTH, and this spirit was once again evident as partners from across Europe reunited in Barcelona. On 29–30 September 2025, the 4th General Assembly Meeting of the project was kindly hosted by Hospital Sant Joan de Déu.
With just over a year left before the end of the project, this meeting was a key opportunity to reflect on progress, share insights, and jointly prepare for the final phases of the clinical trial. Some partners were able to meet in person, while others joined online, ensuring that the whole consortium could take part in this important moment.
Closing the meeting at the end of PCOS Awareness Month added special significance: a reminder of the importance of raising awareness and continuing efforts to bring new, effective treatment options closer to young women with PCOS.
Two days of collaboration and scientific progress in PCOS research
The agenda of the meeting covered a wide range of aspects: updates on the clinical trial status; insights into lifestyle, quality-of-life, and socio-economic impact; discussions on patient management and centricity; as well as trial monitoring and coordination. Partners also reviewed progress in dissemination and communication activities, explored regulatory and exploitation pathways, and discussed project management to ensure alignment for the final year of SPIOMET4HEALTH.
The project is now at a crucial stage. In the words of Lourdes Ibáñez, project coordinator:
“We are currently completing the follow up of the patients. Once this has been finished, we will unlock the database so that the results can be analysed. If our hypothesis proves to be correct and SPIOMET is superior to placebo in normalising the ovulation rate, we will go for commercialization so that we can be able to help millions of women with PCOS”.
Beyond the technical presentations, the meeting was also a valuable moment to exchange ideas, strengthen collaboration, and enjoy time together as a consortium.
SPIOMET4HEALTH and the urge for a PCOS treatment
SPIOMET4HEALTH, which started in 2021 and will run until December 2026, is funded under the Horizon Europe research and innovation programme. The project’s goal is to evaluate a new treatment option for adolescents and young women with Polycystic Ovary Syndrome (PCOS), a condition that affects millions worldwide. By targeting the roots of PCOS, the project aims to bring science closer to women’s everyday lives and open the door to improved treatment options.
PCOS is one of the most common yet underdiagnosed hormonal conditions, affecting around 1 in 10 women of reproductive age worldwide. Beyond its impact on fertility, it is associated with metabolic, cardiovascular, and psychological consequences, which makes research in this field essential. Despite its prevalence, there is still no specific approved treatment for PCOS — a gap that SPIOMET4HEALTH aims to address.
By targeting the roots of PCOS, the project seeks to bring science closer to women’s everyday lives and open the door to improved, patient-centred treatment options. This is why raising awareness is so important: it sheds light on the daily challenges women face, the need for more dedicated research, and the urgency of translating scientific progress into real-life solutions. Each September, this commitment is celebrated during PCOS Awareness Month — making it especially meaningful that our consortium gathered this month to advance our shared mission.
The future of our PCOS treatment research
As the project enters its final stretch, partners remain committed to advancing the clinical trial, maximizing the impact of results, and ensuring that collaboration continues to guide every step of SPIOMET4HEALTH.
The consortium warmly thanks Sant Joan de Déu for their hospitality in Barcelona and all partners for their dedication to this shared mission.
Stay tuned for updates on the SPIOMET4HEALTH clinical trial and follow our progress towards new treatment options for PCOS!
